there are not many success cases of entering the Chinese market through Chinese export licenses.
Here we will analyze the reasons why Korean pharmaceutical companies find it difficult to enter the Chinese market and the demand for Korean pharmaceuticals seen in China,
and describe the strategy and preparation process for entering the Chinese market.
We will discuss the Chinese market access law, clinical citation system, MAH system utilization plan, and export examples of active pharmaceutical ingredients, NCE new drugs classified as Class 1
and Class 2 improved new drugs.
Only with a broad understanding and thorough preparation of the Chinese pharmaceutical market and system can it be considered the fastest path for the Chinese market.
We will provide suggestions on its methods and negotiate in the future.
Brief Introduction of Speaker
In order to enter China, Dasan Pharmaceutical established and operated a formulation research institute located in Shenyang since 2014. Dr Jinho Yoo is responsible for managing the overall operations of
Dasan Pharmaceutical's Shenyang research institute, exporting active pharmaceutical ingredients, obtaining clinical licenses, and conducting research clinical research for health food for Korean pharmaceutical
companies in the Chinese market. The Shenyang Research Institute of Dasan Pharmaceutical has recently obtained a production license through China's MAH system. Also serves as the head of Dasan
Pharmaceutical in the recently established Anhui Heryi Dasan Pharmaceutical JV by the cooperation with a Chinese listed company.
Dr Jinho Yoo also conducts research, process development, and production of raw pharmaceutical products through the independently established Shanghai High Standard Pharm,
while also serving as a active pharmaceutical ingredients and intermediates supplier to pharmaceutical companies in South Korea and China.